Clinical Trial Update: A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Prostate Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating Axumin PET/CT for risk stratification in prostate cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Axumin (fluciclovine F-18)

Snippet

Sponsor: HALO Diagnostics | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-06-04